Health Care·Biotechnology·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.42 | N/A | -14.44% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.42 | N/A | -14.44% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed awareness of the current difficulties but remains focused on future opportunities. They did not provide specific guidance for the upcoming quarters.
Management acknowledged the challenges faced during the quarter.
They emphasized a focus on long-term growth despite short-term setbacks.
Despite missing expectations on EPS, Veracyte's stock rose by 2.28% following the earnings report. This increase may reflect investor optimism about the company's long-term strategy, even in light of current challenges. The lack of revenue data and guidance suggests uncertainty, but the stock's positive reaction indicates some confidence from investors.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
ADOBE INC
Mar 18, 2014